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Abstract 
Vascular dysfunction is one of the major causes of cardiovascular (CV) mortality and 
increases with age. Epidemiological studies suggest that Mediterranean diets and high nut 
consumption reduce CV disease risk and mortality while increasing plasma α-tocopherol. 
Therefore, we have investigated whether almond supplementation can improve oxidative 
stress markers and CV risk factors over 4 weeks in young and middle-aged men.   
Healthy middle-aged men (56+5.8years), healthy young men (22.1+2.9years) and 
young men with two or more CV risk factors (27.3+5years) consumed 50g almond /day for 4 
weeks. A control group maintained habitual diets over the same period. 
Plasma α-tocopherol/cholesterol ratios were not different between groups at 
baseline and were significantly elevated by almond intervention with 50g almond/day for 
four weeks (p<0.05).  Plasma protein oxidation and nitrite levels were not different between 
groups whereas total, HDL and LDL cholesterols and triglycerides were significantly higher in 
healthy middle-aged and young men with CV risk factors but were not affected by almond 
intake. In the almond consuming groups, flow mediated dilatation (FMD) was improved and 
diastolic blood pressure was reduced significantly after 4 weeks, but systolic blood pressure 
was only reduced in healthy men.  
In conclusion, a short-term almond-enriched diet can increase plasma α-tocopherol 
and improve vascular function in asymptomatic healthy mean men aged between 20 and 70 
without effect on plasma lipids or markers of oxidative stress. 
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Introduction 
Ageing is considered the major non-modifiable risk factor for cardiovascular disease (CVD) 
[1]. Independent risk factors for CVD include increased blood lipid concentrations (LDL, 
triacylglycerols and free fatty acids), blood pressure (BP), haemostatic factors, inflammatory 
markers, oxidative stress markers and endothelial dysfunction [2] and each of these risk 
factors is influenced by age [3]. For example, between 40–69 years, each 20 mmHg rise in 
systolic BP or 10 mmHg rise in diastolic BP associates with a two-fold increase in death rate 
from vascular disease [3]. Elevations in BP can be attributed at least in part to arterial 
stiffening, an irreversible process that progresses through all blood vessels during ageing. In 
healthy subjects without confounding risk factors or significant systemic inflammation, a 
more oxidized plasma cysteine/cystine environment correlates with increased arterial 
stiffness [4]. In aorta from old mice with increased total, adventitial and medial advanced 
glycation endproducts (AGEs), vessels were de-stiffened by sodium nitrite therapy 
secondary to decreasing oxidative stress, indicating that it is possible to improve impaired 
vascular reactivity of ageing, an important risk factor for CVD [5]. 
Elevated plasma lipids are important independent risk factors for CVD and typically, total 
cholesterol and the LDL:HDL ratio increase with ageing. For over 40 years, it has been known 
that Mediterranean populations have a low prevalence of coronary heart disease and low 
plasma cholesterol levels despite high total fat consumption; however, saturated fatty acid 
intake is typically low in these populations and the merits of a Mediterranean diet with high 
monounsaturated (MUFA), polyunsaturated fatty acids (PUFA) and antioxidant 
micronutrients were propounded [6]. A number of randomised controlled trials were 
developed to investigate vitamin E and/or α-tocopherol on cardiovascular outcomes with 
the most recent Cochrane review finding no evidence to support antioxidant supplements 
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for primary or secondary prevention of CVD [7]. The epidemiological evidence for disease 
prevention by dietary antioxidants is now considered within a hormesis model whereby 
they exert a paradoxical oxidative activation of the adaptive response transcription factors 
e.g. Nrf2 and processes such as autophagy  which regulate prevention, repair and removal 
of molecular damage [8,9]. In support of this, α-tocopherol has been shown to promote 
autophagy in rat liver and activation of autophagy in the vasculature by spermidine reverses 
arterial ageing[10,11]. The protective effects of the Mediterranean diet most likely reflects 
the combined effects of many nutrients in any given diet or foodstuff working in synergy. 
Almonds are major dietary sources of α-tocopherol and MUFA and frequent nut 
consumption reduces the risk of fatal coronary heart disease, non-fatal myocardial 
infarction [12], and sudden cardiac death  [13]. Additional nutrients in almonds that 
associate with positive cardiovascular outcomes include antioxidant flavanoids and arginine, 
the rate limiting precursor in the biosynthesis of the vasodilatory molecule, nitric oxide. The 
exact nutrient composition of almonds varies with cultivar [14] and the beneficial effects of 
almonds may be due to a combination of nutrients.  
A meta-analysis of dietary almond interventions concluded that the present randomized 
trials do not support almond ingestion for any lipid modifying effects [15]. However, dietary 
intervention with almonds has improved markers of insulin sensitivity in adults with 
prediabetes [16]. Independently, consumption of almonds was shown to influence a few but 
not all markers of inflammation and haemostasis in a dose-independent manner [17]. 
Further study is needed to inform the mechanisms of and populations who can benefit from 
dietary interventions with almonds to reduce CV risk.  
Therefore we have investigated the potential for dietary intervention with almonds to 
increase plasma α-tocopherol concentration and reduce oxidative biomarkers, as a 
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mechanism for reducing risk factors for CVD (reducing BP, improving impaired vascular 
reactivity of ageing and decreasing lipids) in asymptomatic healthy young and older adults.  
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METHODS 
Subjects 
Male participants only were investigated in the present study as the effect of age on CVD 
risk in women is confounded by oestrogen levels and age of menopause[18]. From a pilot 
study which showed effects from 50g/d but not 25g almonds/d over 4 weeks, we calculated 
that a sample size of 15 subjects per group was needed to power the study to detect a 5% 
difference in BP, lipids and a 10% change in flow mediated dilatation after intervention with 
80% power and 95% probability. Therefore, 60 males who were resident in the United 
Kingdom were recruited to the study and were grouped by age and health status. 
Participants were excluded if they were taking prescribed medication for lipid management, 
diabetes or if they were smokers, regular users of antioxidant supplements and taking anti-
inflammatory drugs. Ethical approval for the study was provided by Aston University Ethics 
committee. 
Group 1 subjects; “healthy middle-aged” men, comprised of 20 men aged over 55 years with 
fasting (12 h) plasma triacylglycerol < 220mg/dL, or total cholesterol < 250mg/dL.  One in 
four of subjects recruited to this group were assigned to the habitual diet group, Group 4. 
Group 2 subjects; “healthy young” men, comprised of 20 men aged between 18 and 35 
years of age, with fasting (12 h) plasma triacylglycerol < 220mg/dL, or total cholesterol < 
250mg/dL, blood and body mass index (BMI) between 17 and 22.5. One in four of subjects 
recruited were assigned to the habitual diet group, Group 4.  
Group 3 subjects; “young, at risk” for cardiovascular disease men, comprised of 20 men 
aged between 18 and 35 years of age, with at least one risk factor (lipids, BP, BMI) above 
the normal range. One in four of subjects recruited were assigned to the habitual diet 
group, Group 4.  
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Group 4 subjects; (control) comprised 15 male subjects >18 years of age. Five subjects were 
randomly assigned to this group from each of the three groups above.  
Experimental design 
A four week almond supplementation design was used because plasma lipid and lipoprotein 
concentrations stabilize within 2–3 weeks of altering diet [19]. Subjects were recruited 
throughout the year to avoid seasonal dietary effects in nutrient intake. Subjects consumed 
either their habitual diet (group 4) or were asked to substitute any daily snack for 2 bags of 
almonds (50g) and otherwise to eat to satiety (groups 1-3). Almonds provided 14mg α-
tocopherol per 50g and the monounsaturated fatty acid, oleic acid was the major fatty acid 
constituent, exceeding 50% of mass. 
Compliance with the intervention diet was assessed with 3-day food diaries, including a 
weekend day and bag return. Compliance exceeded 92%. Estimated dietary intakes were 
calculated with DietPlan6 software programme (Forestfield Software, Horsham). 
Six participants assigned to the control group withdrew after 4 weeks. All other subjects 
continued throughout the study. Procedures involving human subjects were approved by 
the Aston University ethical committee.   
Fasting blood samples (baseline and after 4 weeks almonds) were collected into EDTA and 
centrifuged at 498 x g (Heraeus instruments labofuge 400R) for 10mins within 2 hours of 
collection. The plasma was separated and aliquoted and stored at -80oC until required for 
analysis. Aliquots were not freeze-thawed.  
Plasma lipid determinations 
Triacylglycerol and cholesterol concentrations were measured enzymatically with CHOD-PAP 
kits from Randox, Ireland. Each assay included appropriate standards and calibrators. 
Interassay coefficients of variation (CV)s were 3.5% for triacylglycerol and 5.1% for 
8 
 
cholesterol analysis. HDL was separated from the plasma by precipitation with dextran 
sulfate and magnesium chloride and cholesterol was analysed by CHOD-PAP. The CV for HDL 
cholesterol analysis was 2.5%.  
Blood pressure, BMI and flow mediated dilatation (FMD) 
BP measurements were taken twice from volunteers after sitting for 5 minutes with the 
brachial artery level with the heart, using a manual sphygmomanometer.  
Blood flow measurements were obtained by venous occlusion plethysmography. The 
venous flow in the forearm was stopped using a sphygmomanometer for 10sec at 40mmHg 
whilst still allowing arterial flow. After releasing the pressure, the rate at which venous flow 
returned to normal was calculated.  The CV for flow mediated dilatation measurements 
taken on three separate days from the same individual was 6.9%. 
BMI was measured as body weight in Kg divided by the square of the height in metres. 
Protein carbonyl determination 
Plasma protein carbonyls represent the steady state rate of protein synthesis, oxidation and 
removal which can be influenced by nutrients that affect free radical formation and 
expression of clearance pathways [20]. Here carbonyls were analysed to provide insight into 
the systemic steady state of protein oxidation following almond intervention and were 
determined by ELISA as previously described by Carty et al[21]. 
α-tocopherol analysis 
Plasma aliquots (300µl) were thawed with addition of 300µl of ethanol (containing 80µM α-
tocopherol acetate as internal standard). Following hexane extraction in the presence of 2, 
6-di-tert-butyl-4-methylphenol, the organic phase was evaporated to dryness, then 
reconstituted with 300µl methanol[22]. Reverse phase chromatography (Phenomenex 
Gemini 5 micron C18 110A column) was used to separate α-tocopherol levels in plasma. α-
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tocopherols were eluted using methanol at a flow rate of 1ml/min with detection at 292nm. 
Between batch accuracy of analysis was 5.3 %. 
Plasma nitrite analysis 
Plasma nitrites were determined using a fluorimetric assay kit according to the 
manufacturer’s instructions with modification to remove proteins (Cayman Chemical 
Company Cat. No. 780051).  
Statistical analysis 
Analyses were carried out with GraphPad Prism. The results are given as means ± SDs unless 
otherwise noted. Changes over time were examined with repeated-measures analysis of 
variance. If a significant time effect (P < 0.05) was obtained, individual time points were 
compared by using the Tukey-Kramer adjustment. Correlations among variables were 
calculated by using Pearson's product-moment correlation coefficients. 
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RESULTS 
Subjects 
The mean age of subjects recruited into group 1 was significantly higher than all other 
groups (p<0.001; Table 1).  Consistent with the effects of ageing on metabolism, total 
plasma cholesterol levels were significantly higher in the healthy, middle-aged adult group 
(181mg/dL) compared to the habitual diet group (152mg/dL) and healthy, young group 
(154mg/dL) at baseline (p=0.03). The total plasma cholesterol and LDL cholesterol 
concentrations were similar in the healthy, middle-aged population to the younger, at risk 
group. However, HDL cholesterol concentration was significantly increased in the healthy 
middle-aged adult population (58.0+10.75mg/dL) compared to all other groups (healthy 
younger: 49.85+9mg/dL; younger at risk: 47.44+7.50mg/dL; habitual diet group: 
53.27+15.0mg/dL; p<0.001). Plasma triacylglycerol concentrations were elevated 
significantly in the young, risk group (138 + 31mg/dL) compared to other subjects enrolled 
into the study (healthy middle-aged: 124.00 + 28.50mg/dL; healthy younger: 119.70 + 
20mg/dL; habitual diet group: 123 + 33.0mg/dL; p<0.001). 
In order to identify any association between age and established cardiovascular risk factors 
in the total recruited population at baseline, correlation analysis was performed; significant 
correlations were observed between age with total cholesterol (p=0.001), age with HDL 
cholesterol (p<0.05)  and age with diastolic BP (p<0.001).  
Dietary intakes by subjects 
BMI, food composition analysis and calorie intake were recorded to inform any effects of 
almond intake on dietary habits and body weight. Dietary habits during the intervention 
were analysed using Dietplan 6 (Table 2).  Prior to the study, total fat intake for the cohort 
was ~30% of calories. During the intervention, total dietary fat was increased significantly to 
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an estimated 36% of calories in the healthy, middle-aged group only (p=0.003); this effect 
was reflected in an increase in MUFA and PUFA intakes. Dietary analysis of all intervention 
group diaries showed a significant increase in estimated MUFA intake (p<0.02). After the 
intervention, there was a general trend for reduced saturated fat and cholesterol intake 
compared to the start of the study. BMI was elevated significantly over four weeks in the 
habitual diet (no almond control) and the young group, but neither the “at risk” group nor 
the healthy, middle-aged group showed any change in BMI with almond intake (data not 
shown). 
Effects of almond supplementation on plasma protein oxidation, nitrite and α-tocopherol 
Plasma α-tocopherol corrected for LDL concentration was not different between groups at 
baseline and was increased significantly from 6.6+0.4mmol α-tocopherol/mol LDL to 
6.8+0.44mmol α-tocopherol/mol LDL after 50g/d almonds (mean+SEM). There was no 
correlation between plasma α-tocopherol/LDL for any measure of vascular function. 
Plasma nitrite and protein carbonyl concentrations were not different between any of the 
study groups and remained unchanged after intake of 50g/d almonds for 4 weeks 
(carbonyls; 2.9+0.17nmol/mg at week 0 compared to 2.8+0.16nmol/mg at week 4 and 
nitrite; 5.6+0.52 at week 0 compared with 5.8+0.55 at week 4) 
 
Effect of almond intake on plasma cholesterol and triacylglycerol concentrations.  
Plasma cholesterol concentrations of subjects in all groups were measured to determine 
whether almond consumption had any effect on lipid distribution. Intervention with 
almonds had no significant effect on total plasma cholesterol concentrations in any group 
and the cholesterol concentration in the habitual diet group did not change over the period 
of study.  
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Plasma triacylglycerol HDL-, and LDL-cholesterol concentrations remained unchanged after 
intake of 50g/d almonds for 4 weeks  
Using two-way ANOVA, the between group triacylglycerol, total, LDL and HDL cholesterol 
concentrations remained significantly different after almond intervention. 
Effect of almond intake on blood pressure and vascular reactivity 
The diastolic BPs of subjects within the healthy middle-aged and healthy younger groups 
decreased significantly (-6% and -12% respectively) after 50g almonds per day for four 
weeks (Figure 1a; P= 0.015 and 0.002 respectively). Diastolic BP remained unchanged in the 
young, at risk group after almonds and in the group that remained on their habitual diet.  
In all intervention groups, systolic BP was decreased significantly following 50g almonds/day 
for 4 weeks (Figure 1b; p<0.01, by -6% within the healthy middle-aged, -5% within the 
healthy young and -4% in the young at risk group) but the control group who maintained 
their habitual diet showed no change in systolic BP.  There was a significant difference in 
systolic BP between subject groups (p<0.001) at baseline which remained after intervention. 
In a follow-up phase of the study (8 weeks on a habitual diet without almonds), we 
observed that systolic BP returned to pre-almond diet levels (data not shown). 
Hyperemic reactive blood flow following vessel occlusion was investigated as a measure of 
the effect of the almond-enriched diet on vascular function and was analysed during the 
early morning to eliminate confounding by diurnal variation. There were no inter-group 
differences in flow mediated dilatation (FMD) at the start of the study, although older adults 
and young at risk subjects had lower median FMD. However, a significant increase in FMD 
was observed after 50g almonds per day for four weeks in the young groups and a trend for 
increase was observed in the older adults with 12/15 showing an improvement in blood 
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flow (p=0.03; Figure 2). There was a trend for a reduction in blood flow in the subjects who 
maintained a habitual diet (p<0.2).  
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Discussion 
In the present study we have shown that an almond enriched diet can reduce BP and 
improve vascular function but not lipid profiles in middle-aged, healthy subjects and 
younger subjects with and without risk factors for CVD. Despite the elevation of plasma α-
tocopherol following almond intervention, no other parameters measured here relating to 
oxidation (nitrite formation or protein carbonyls) were influenced by the dietary change. 
This is consistent with previous supplementation studies that have attempted 
unsuccessfully to address cardiovascular risk with α-tocopherol supplementation based on a 
hypothesis that vitamin E is exerting an antioxidant effect[23]. Nevertheless, the data 
reported here confirm the suggestion that α-tocopherol is acting hermetically e.g. through 
promoting autophagic clearance of intracellular fibrotic proteins [11] or is a correlate for 
nutrients which may improve cardiovascular health, such as MUFA which are anti-
inflammatory in vitro and in vivo [17,24]. Epidemiological evidence suggests that 
consumption of a diet enriched in MUFA and tocopherols including nuts, reduces BP and 
lipid levels [6,25-27]. Indeed, frequent nut consumption of between 1-4 times per week has 
been reported to reduce risk of CVD mortality by ~25% [28].  
Muscle relaxation in response to sympathetic activity can be measured as FMD [29]. FMD is 
influenced by the bioavailability of nitric oxide which may be consumed by reaction with 
superoxide anion radicals that are produced during inflammation. Almonds are enriched in 
arginine, a rate-limiting substrate for endothelial nitric oxide synthesis and in vitamin E, a 
free radical scavenger and together are predicted to increase bioavailable nitric oxide and 
FMD. FMD, which has been used as predictive tool for future CVD events [30], was lower  in 
younger, at risk subjects when compared to subjects in the other groups.  FMD was 
improved significantly in the supplemented cohort after 50g almond per day, with the 
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greatest benefit being observed in the at risk group. Nitrite levels were unaffected, 
however. 
Age-dependent vascular stiffness may also be dependent on reduced baroreceptor reflex 
activity, typically seen as postural hypotension in older adults [31].  The mechanisms of 
baroreceptor control by nutrients are not well understood, however, recent reports have 
suggested that redox imbalances induces hypertensive and baroreflex responses in rates 
and that tocopherol delivered pre-natally can modulate vascular responses in hypoxia  
[32,33]. In addition, lipid abnormalities may mediate this effect; hyperlipidemia in obese 
hypertensive individuals has been attributed to impairment of the baroreceptor reflex 
leading to increased BP [34]. In pre-diabetes subjects with insulin resistance, no 
improvement of systolic BP was noted after almond consumption [16,35].. In the present 
study, systolic BP was decreased significantly in all intervention groups but not the control 
group who maintained their habitual diet and did not consume almonds. Diastolic BP was 
significantly reduced with almond supplementation in healthy subjects only, irrespective of 
age. Systolic BP reduction has been suggested as a more important target for reduction in 
older adults to reduce cardiovascular events[36].  
The relationship between BP and age remained significant in this cohort after almond 
intake, probably reflecting the multiple facets of vascular elasticity that undergo irreversible 
change during ageing e.g. oxidation or glycation of matrix proteins [37]. 
In the present study, the difference in cholesterol concentrations between middle-aged and 
young subjects are not mitigated by following an almond-enriched diet for 4 weeks, and the 
age-associated correlation with cholesterol and LDL-cholesterol concentration remains 
significant after a four week intervention with 50g almonds per day. This supports the 
premise that ageing-induced changes in metabolism are responsible for increased plasma 
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lipids, and that while changing to a vitamin E and MUFA-enriched diet can improve the 
elevated lipid profile, the age-effect remains.   
We have demonstrated here that dietary almond intake improved markers of vascular 
function. Despite an additional 300kcal to the dietary energy intake, no significant intake in 
calories was reported in the food diaries for any group nor was there any significant change 
in BMI in the intervention groups suggesting energy compensation by subjects; this 
compensation effect has been reported in previous studies with almond snacks [38]. It has 
been reported previously that nut intake increases satiety, which may explain the reduction 
in calories consumed from non-almond foods [39]. 
In summary, the higher BPs and lipid concentrations observed in men with increasing age is 
still evident after an almond enriched diet, nevertheless, similar to younger adults, middle-
aged adults do benefit from increased almond intake (50g/d; 4 weeks) with improvements 
in vascular function that are expected to reduce risk of CVD. 
In an ageing population with substantial CVD morbidity and mortality, interventions that 
decrease the incidence and/or severity of CVD in middle-aged adults are expected to have a 
major impact on global health and related health care costs.  
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Tables 
Table 1 –Subject characteristics classified by intervention group 
 Healthy middle-
aged 
Healthy young Young at risk Control P value 
Age (years) 56.07 (+ 5.77) 22.14 (+2.88)* 27.27 (+5.04)* 23.00 (+5.87)* * P<0.001 v 
healthy, 
middle-aged 
BMI 25.37 + 4.041 19.99 +1.595*+ 26.34 + 4.321 22.20 + 2.260+ *p<0.05  v 
healthy 
middle-aged 
+ v risk 
Systolic blood 
pressure 
(mmHg) 
134.3 + 23.09 119.6 + 12.51 127.4 + 6.967 119.7 + 11.50 NS, p>0.05 
Diastolic 
blood 
pressure 
(mmHg) 
84.7+9.8  73.3+ 7 79.1 + 8.8 68.8 + 9.0 NS, p>0.05 
Cholesterol 
(mg/dL) 
181+25.1 154+28.57* 181+44.4 152+28.6* * P<0.05 v 
healthy 
middle-aged 
LDL (mg/dL) 116.10+30.45  93.47+24.60*+ 118.70+40.54 87.92+25.70*+ * P<0.001 v 
healthy 
middle-aged 
+ v risk 
HDL (mg/dL) 58.0+10.75+ 49.85+9.0* 47.44+7.50* 53.27+15.0*+ * P<0.001 v 
healthy 
middle-aged 
+ v risk 
Triacylglycerol 
(mg/dL) 
124.00 + 28.50+  119.70+ 20.00*+ 138 + 31*
  
123 + 33.00+
  
* P<0.001 v 
healthy 
middle-aged 
+ v risk 
 
V = compared with 
NS = not significant  
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Table 2 - Dietary habits during the intervention were examined using self-reporting 3-day 
diet diaries  
Food diary 
analysis 
intervention 
Healthy 
middle-
aged 
Healthy 
young 
Young at risk control 
Total dietary 
fat intake (g/d) 
0g almonds 75.0 + 6.0 77.3 + 9.8  75.5 + 11.5  79.7 + 9.8  
habitual 4 
weeks  
- -  -  74.6 + 11.3   
50g/d 4weeks 96.4 + 4.9**  76.7 + 6.5 74.6 + 7.7  - 
MUFA intake 
(g/d) 
0g almonds 21.3 + 2.1  26.3 + 4.7  24.6 + 4  26.1 + 4.7  
habitual 4 
weeks 
 - -  -   25.8 + 4.5  
50g/d 4weeks 
39.6 + 
1.7***  
39.8 + 
2.6 ** 
33.3 + 2.5 * - 
PUFA intake 
(g/d) 
0g almonds 11.5 + 1.2  17.6 + 4 11.4 + 1.9  13.2 + 1.2  
habitual 4 
weeks 
-  -  -  10.1 + 1.0*  
50g/d 4weeks  17.3 + 1** 16.9 + 0.6  13.3 + 1.3  -  
Calorie intake 
(kcal/d) 
0g almonds 2050 + 107  2211 + 265  2128 + 341  2131 + 237 
 
habitual 4 
weeks 
 - -  -  1941 + 237 
  50g/d 4weeks 
2268 + 
143*  
2583 + 129 1944 39 - 
*  P<0.05 
** P< 0.01 
*** P<0.001
23 
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Figure Legends 
 
Figure 1. Blood pressure (a – diastolic; b – systolic) was determined by venous 
plethysmography in each subject at baseline and following four weeks of almond 
intervention with 50g almonds/day (d). Data are expressed as box and whisker plots with 
the box showing median and 75% confidence intervals and data range shown as whiskers 
where * represents p<0.05 and ** represents p<0.01.  
 
Figure 2. Flow mediated dilatation was measured in each subject at baseline, following four 
weeks 25g almonds/day (d) and following four weeks of almond intervention (50g/d). Data 
are expressed as box and whisker plots with the box showing median and 75% confidence 
intervals and data range shown as whiskers where * represents p<0.05 and ** represents 
p<0.01.  
 
 
 
